Castle Biosciences Inc

Health Care
Medical Specialities
www.castlebiosciences.com

Earnings Score
Moat Score
Safety Score

Market Cap $858.95M
PE 141
Debt $10.20M
Cash $94.96M
EV $774.19M
FCF $34.54M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$6.08M
EBIT	$11.56M
ROE	1%
ROA	2%
FCF	$34.54M
Equity	$441.06M
Growth Stability	1
PE	141.39
PEG	196.16
PB	1.95
P/FCF	24.87
P/S	2.75
Price/Cash	0.11
Debt/Equity	0.02
Debt/FCF	0.3
Net Margins	4%
Gross Margins	82%
Op. Margins	4%
Earnings CAGR	0%
Sales Growth YoY	39%
Sales Growth QoQ	-1%
Sales CAGR	47%
FCF CAGR	3%
Equity CAGR	31%
Earnings Stability	-0.43
Earnings Growth YoY	-133%

Earnings Growth QoQ	-75%
Earnings CAGR 5Y	1%
Sales CAGR 5Y	46%
FCF CAGR 5Y	8%
Equity CAGR 5Y	28%
Earnings CAGR 3Y	58%
Sales CAGR 3Y	58%
Equity CAGR 3Y	1%
Market Cap	$858.95M
Revenue	$311.88M
Assets	$514.57M
Total Debt	$10.20M
Cash	$94.96M
Shares Outstanding	27.66M
EV	774.19M
Earnings Score	6%
Moat Score	37%
Safety Score	98%
Final Score	47%
Working Capital	300.48M
Current Ratio	7.78
Gross Profit	$255.43M
Shares Growth 3y	4%
Equity Growth QoQ	4%
Equity Growth YoY	14%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

SEC Filings

Direct access to Castle Biosciences Inc (CSTL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Castle Biosciences Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Castle Biosciences Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability -43%

loading chart...

Castle Biosciences Inc Discounted Cash Flow

Fully customizable DCF calculator online for Castle Biosciences Inc.

Years

Calculation mode

= $433M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$35M	$36M	$37M	$38M	$39M	$41M	$42M	$43M	$45M	$46M	$48M	$478M
DCF		$32M	$30M	$29M	$27M	$25M	$24M	$22M	$21M	$20M	$18M	$184M
Value	$433M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-45%	6%	-16%	-33%	-49%	-26%	4%
ROA	-	8%	-1%	-9%	-15%	-13%	2%
ROE	-	4%	-2%	-8%	-17%	-15%	1%

Bad Net Margins (3.52%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	5.35	0	-	-	-0	0.3
Debt over Equity	-0.43	0.38	0	-	-	0	0.02
Growth Stability	-	-	-	-	-	-	1

Good Debt/FCF ratio (0.3)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.02)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	128%	21%	50%	46%	60%	46%
Earnings YoY growth	-	-129%	-444%	204%	115%	-14%	1%
Equity YoY growth	-	-250%	388%	-1%	-3%	-2%	28%
FCF YoY growth	-	-148%	-16%	-539%	110%	-59%	8%